The incidence of ZES ranges from 0.1%-1% of patients with peptic ulcer disease and is more common in males than in females. Most patients are diagnosed between ages 20-50, although the time span from symptoms to diagnosis is typically greater than 5 years due to the wide availability of acid-suppressing medications. 70%-80% of gastrinomas are sporadic, and 20%-30% are secondary to multiple endocrine neoplasia type 1 (MEN1). Gastrinomas typically arise in the duodenum and are one of the most common functional pancreatic neuroendocrine tumors. In contrast with pancreatic gastrinomas, duodenal gastrinomas are generally small (<1 cm), often multiple, and more likely to have metastasized to the liver at the time of diagnosis. In a small percentage of patients, gastrinomas arise in a nonpancreatic or nonduodenal site, including the stomach and ovary.
Abdominal pain and chronic diarrhea are the most common presenting symptoms of ZES, each seen in approximately 75% of patients. Other common symptoms include heartburn, weight loss, and gastrointestinal bleeding.
E16.4 – Increased secretion of gastrin
53132006 – Zollinger-Ellison syndrome
- Antral G-cell hyperplasia – Characterized by poor response to secretin stimulating test and absence of gastrinoma on imaging.
- Retained antrum syndrome – Presents as recurrent peptic ulcers following gastrectomy. Gastrin elevation is modest compared to ZES.
- Sporadic peptic ulcer disease
- Celiac disease
- Gastric malignancy
- Chronic pancreatitis
- Atrophic gastritis
- Acid-suppressive medications